Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CTRC | Q99895 | 6/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IL1RN | P18510 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952097 | 0.88 | NPC1 (0.55) | ELANENPC1RAB9ACTRCCASP3 | |
| SCHEMBL23835788 | 0.88 | NPC1 (0.58) | ELANENPC1RAB9ACTRCCASP3 | |
| SCHEMBL1039441 | 0.85 | NPC1 (0.54) | ELANENPC1RAB9ACTRCCASP3 | |
| SCHEMBL1039440 | 0.85 | NPC1 (0.54) | ELANENPC1RAB9ACTRCCASP3 | |
| SCHEMBL4902533 | 0.84 | NPC1 (0.53) | ELANENPC1RAB9ACASP3MAOB | |
| SCHEMBL12273254 | 0.84 | NPC1 (0.53) | ELANENPC1RAB9ACASP3MAOB | |
| SCHEMBL27691482 | 0.83 | NPC1 (0.51) | ELANENPC1RAB9ACASP3MAOB | |
| SCHEMBL27691483 | 0.83 | NPC1 (0.51) | ELANENPC1RAB9ACASP3MAOB | |
| SCHEMBL8646687 | 0.79 | NPC1 (0.62) | ELANENPC1RAB9ACTRCCASP3 | |
| SCHEMBL8309719 | 0.79 | ELANE (0.46) | ELANECTRCCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | ACE, ACE2, TMPRSS2 | ELANE 242/4885NPC1 649/4885RAB9A 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.